Defining drug/drug class refractoriness vs lines of therapy in relapsed/refractory multiple myeloma

被引：13

作者：

Goel, Utkarsh ^{[1
]}

Charalampous, Charalampos ^{[1
]}

Kapoor, Prashant ^{[1
]}

Binder, Moritz ^{[1
]}

Buadi, Francis K. ^{[1
]}

Dingli, David ^{[1
]}

Dispenzieri, Angela ^{[1
]}

Fonder, Amie ^{[1
]}

Gertz, Morie A. ^{[1
]}

Gonsalves, Wilson I. ^{[1
]}

Hayman, Suzanne R. ^{[1
]}

Hobbs, Miriam A. ^{[1
]}

Hwa, Yi L. ^{[1
]}

Kourelis, Taxiarchis ^{[1
]}

Lacy, Martha Q. ^{[1
]}

Leung, Nelson ^{[1
]}

Lin, Yi ^{[1
]}

Warsame, Rahma M. ^{[1
]}

Kyle, Robert A. ^{[1
]}

Rajkumar, S. Vincent ^{[1
]}

Kumar, Shaji K. ^{[1
]}

机构：

[1] Mayo Clin, Div Hematol, Rochester, MN 55902 USA

来源：

BLOOD CANCER JOURNAL | 2023年 / 13卷 / 01期

关键词：

DOUBLE-BLIND; OPEN-LABEL; DEXAMETHASONE; BORTEZOMIB; MULTICENTER; CARFILZOMIB; GUIDELINES; PLACEBO;

D O I：

10.1038/s41408-023-00785-y

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页数：4

共 15 条

[1] Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study [J].

Dimopoulos, Meletios A. ;

Moreau, Philippe ;

Palumbo, Antonio ;

Joshua, Douglas ;

Pour, Ludek ;

Hajek, Roman ;

Facon, Thierry ;

Ludwig, Heinz ;

Oriol, Albert ;

Goldschmidt, Hartmut ;

Rosinol, Laura ;

Straub, Jan ;

Suvorov, Aleksandr ;

Araujo, Carla ;

Rimashevskaya, Elena ;

Pika, Tomas ;

Gaidano, Gianluca ;

Weisel, Katja ;

Goranova-Marinova, Vesselina ;

Schwarer, Anthony ;

Minuk, Leonard ;

Masszi, Tamas ;

Karamanesht, Ievgenii ;

Offidani, Massimo ;

Hungria, Vania ;

Spencer, Andrew ;

Orlowski, Robert Z. ;

Gillenwater, Heidi H. ;

Mohamed, Nehal ;

Feng, Shibao ;

Chng, Wee-Joo .

LANCET ONCOLOGY, 2016, 17 (01) :27-38

[2] International staging system for multiple myeloma [J].

Greipp, PR ;

San Miguel, J ;

Durie, BGM ;

Crowley, JJ ;

Barlogie, B ;

Bladé, J ;

Boccadoro, M ;

Child, JA ;

Harousseau, JL ;

Kyle, RA ;

Lahuerta, JJ ;

Ludwig, H ;

Morgan, G ;

Powles, R ;

Shimizu, K ;

Shustik, C ;

Sonneveld, P ;

Tosi, P ;

Turesson, I ;

Westin, J .

JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (15) :3412-3420

[3] REGRESSION MODELING STRATEGIES FOR IMPROVED PROGNOSTIC PREDICTION [J].

HARRELL, FE ;

LEE, KL ;

CALIFF, RM ;

PRYOR, DB ;

ROSATI, RA .

STATISTICS IN MEDICINE, 1984, 3 (02) :143-152

[4] Gaps and opportunities in the treatment of relapsed-refractory multiple myeloma: Consensus recommendations of the NCI Multiple Myeloma Steering Committee [J].

Kumar, Shaji ;

Baizer, Lawrence ;

Callander, Natalie S. ;

Giralt, Sergio A. ;

Hillengass, Jens ;

Freidlin, Boris ;

Hoering, Antje ;

Richardson, Paul G. ;

Schwartz, Elena I. ;

Reiman, Anthony ;

Lentzsch, Suzanne ;

McCarthy, Philip L. ;

Jagannath, Sundar ;

Yee, Andrew J. ;

Little, Richard F. ;

Raje, Noopur S. .

BLOOD CANCER JOURNAL, 2022, 12 (06)

[5] Venetoclax or placebo in combination with bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma (BELLINI): a randomised, double-blind, multicentre, phase 3 trial [J].

Kumar, Shaji K. ;

Harrison, Simon J. ;

Cavo, Michele ;

de la Rubia, Javier ;

Popat, Rakesh ;

Gasparetto, Cristina ;

Hungria, Vania ;

Salwender, Hans ;

Suzuki, Kenshi ;

Kim, Inho ;

Punnoose, Elizabeth A. ;

Hong, Wan-Jen ;

Freise, Kevin J. ;

Yang, Xiaoqing ;

Sood, Anjla ;

Jalaluddin, Muhammad ;

Ross, Jeremy A. ;

Ward, James E. ;

Maciag, Paulo C. ;

Moreau, Philippe .

LANCET ONCOLOGY, 2020, 21 (12) :1630-1642

[6] Efficacy and safety of oral panobinostat plus subcutaneous bortezomib and oral dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma (PANORAMA 3): an open-label, randomised, phase 2 study [J].

Laubach, Jacob P. ;

Schjesvold, Fredrik ;

Mariz, Mario ;

Dimopoulos, Meletios A. ;

Lech-Maranda, Ewa ;

Spicka, Ivan ;

Hungria, Vania T. M. ;

Shelekhova, Tatiana ;

Abdo, Andre ;

Jacobasch, Lutz ;

Polprasert, Chantana ;

Hajek, Roman ;

Illes, Arpad ;

Wrobel, Tomasz ;

Sureda, Anna ;

Beksac, Meral ;

Goncalves, Iara Z. ;

Blade, Joan ;

Rajkumar, S. Vincent ;

Chari, Ajai ;

Lonial, Sagar ;

Spencer, Andrew ;

Maison-Blanche, Pierre ;

Moreau, Philippe ;

San-Miguel, Jesus F. ;

Richardson, Paul G. .

LANCET ONCOLOGY, 2021, 22 (01) :142-154

[7] Management of Newly Diagnosed Symptomatic Multiple Myeloma: Updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) Consensus Guidelines 2013 [J].

Mikhael, Joseph R. ;

Dingli, David ;

Roy, Vivek ;

Reeder, Craig B. ;

Buadi, Francis K. ;

Hayman, Suzanne R. ;

Dispenzieri, Angela ;

Fonseca, Rafael ;

Sher, Taimur ;

Kyle, Robert A. ;

Lin, Yi ;

Russell, Stephen J. ;

Kumar, Shaji ;

Bergsagel, P. Leif ;

Zeldenrust, Steven R. ;

Leung, Nelson ;

Drake, Matthew T. ;

Kapoor, Prashant ;

Ansell, Stephen M. ;

Witzig, Thomas E. ;

Lust, John A. ;

Dalton, Robert J. ;

Gertz, Morie A. ;

Stewart, Keith ;

Rajkumar, S. Vincent ;

Chanan-Khan, Asher ;

Lacy, Martha Q. .

MAYO CLINIC PROCEEDINGS, 2013, 88 (04) :360-376

[8] Impact of prior treatment on patients with relapsed multiple myeloma treated with carfilzomib and dexamethasone vs bortezomib and dexamethasone in the phase 3 ENDEAVOR study [J].

Moreau, P. ;

Joshua, D. ;

Chng, W-J ;

Palumbo, A. ;

Goldschmidt, H. ;

Hajek, R. ;

Facon, T. ;

Ludwig, H. ;

Pour, L. ;

Niesvizky, R. ;

Oriol, A. ;

Rosinol, L. ;

Suvorov, A. ;

Gaidano, G. ;

Pika, T. ;

Weisel, K. ;

Goranova-Marinova, V. ;

Gillenwater, H. H. ;

Mohamed, N. ;

Aggarwal, S. ;

Feng, S. ;

Dimopoulos, M. A. .

LEUKEMIA, 2017, 31 (01) :115-122

[9] Isatuximab, carfilzomib, and dexamethasone in relapsed multiple myeloma (IKEMA): a multicentre, open-label, randomised phase 3 trial [J].

Moreau, Philippe ;

Dimopoulos, Meletios-Athanasios ;

Mikhael, Joseph ;

Yong, Kwee ;

Capra, Marcelo ;

Facon, Thierry ;

Hajek, Roman ;

Spicka, Ivan ;

Baker, Ross ;

Kim, Kihyun ;

Martinez, Gracia ;

Min, Chang-Ki ;

Pour, Ludek ;

Leleu, Xavier ;

Oriol, Albert ;

Koh, Youngil ;

Suzuki, Kenshi ;

Risse, Marie-Laure ;

Asset, Gaelle ;

Mace, Sandrine ;

Martin, Thomas .

LANCET, 2021, 397 (10292) :2361-2371

[10] Guidelines for determination of the number of prior lines of therapy in multiple myeloma [J].

Rajkumar, S. Vincent ;

Richardson, Paul ;

Miguel, Jesus F. San .

BLOOD, 2015, 126 (07) :921-922

← 1 2 →